Form 4: Inovio Pharmaceuticals Director Simon X. Benito Reports Stock Option and Restricted Stock Unit Grants

Director Simon X. Benito reports the acquisition of stock options and restricted stock units in Inovio Pharmaceuticals.

Summary

• On May 21, 2024, Simon X. Benito, a director of Inovio Pharmaceuticals, received stock options for 2,917 shares and 2,167 restricted stock units (RSUs).
• The options have an exercise price of $10.99 and vest 100% on May 21, 2025, expiring on May 21, 2034.
• The RSUs also vest 100% on May 21, 2025, and each RSU represents a right to receive one share of common stock.
• Following these transactions, Benito directly owns 2,917 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine equity grant to a director, which is generally viewed as a positive sign of aligning interests. There are no indications of negative performance or concerns.

Positives

• The grant of stock options and RSUs aligns the director's interests with those of the shareholders, incentivizing value creation.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

This type of equity grant is a common practice in the pharmaceutical industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Equity compensation for board members is a common practice across the pharmaceutical industry.
• Companies like Moderna and BioNTech also utilize stock options and restricted stock units as part of their director compensation packages.
• The vesting schedules and option terms are generally in line with industry standards, typically vesting over one to four years.

Stakeholder Impact

• The equity grants could potentially increase shareholder value if the director's performance leads to company growth.
• The grants incentivize the director to act in the best interests of the shareholders.

Key Dates